IDEXX Laboratories, Inc. $IDXX Shares Sold by EFG Asset Management North America Corp.

EFG Asset Management North America Corp. reduced its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 8.5% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,125 shares of the company’s stock after selling 1,028 shares during the period. IDEXX Laboratories comprises 0.8% of EFG Asset Management North America Corp.’s investment portfolio, making the stock its 26th biggest position. EFG Asset Management North America Corp.’s holdings in IDEXX Laboratories were worth $5,964,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the company. Stratos Wealth Partners LTD. increased its stake in IDEXX Laboratories by 1.7% in the 2nd quarter. Stratos Wealth Partners LTD. now owns 1,051 shares of the company’s stock valued at $564,000 after purchasing an additional 18 shares in the last quarter. Red Spruce Capital LLC increased its stake in IDEXX Laboratories by 1.1% in the 2nd quarter. Red Spruce Capital LLC now owns 1,701 shares of the company’s stock valued at $912,000 after purchasing an additional 19 shares in the last quarter. Huntington National Bank increased its stake in IDEXX Laboratories by 0.5% in the 2nd quarter. Huntington National Bank now owns 3,651 shares of the company’s stock valued at $1,958,000 after purchasing an additional 19 shares in the last quarter. Phoenix Financial Ltd. increased its stake in IDEXX Laboratories by 1.7% in the 2nd quarter. Phoenix Financial Ltd. now owns 1,181 shares of the company’s stock valued at $633,000 after purchasing an additional 20 shares in the last quarter. Finally, Rise Advisors LLC increased its stake in IDEXX Laboratories by 3.9% in the 2nd quarter. Rise Advisors LLC now owns 562 shares of the company’s stock valued at $301,000 after purchasing an additional 21 shares in the last quarter. 87.84% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

IDXX has been the subject of several research analyst reports. BTIG Research raised their price objective on IDEXX Laboratories from $785.00 to $830.00 and gave the company a “buy” rating in a research note on Tuesday. Stifel Nicolaus set a $775.00 price objective on IDEXX Laboratories in a research note on Monday. Leerink Partners set a $785.00 price target on IDEXX Laboratories in a research report on Monday. Morgan Stanley raised their price target on IDEXX Laboratories from $765.00 to $805.00 and gave the stock an “overweight” rating in a research report on Tuesday. Finally, Wall Street Zen downgraded IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Sunday, September 28th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $730.50.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, EVP Sharon E. Underberg sold 5,450 shares of the business’s stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $651.60, for a total transaction of $3,551,220.00. Following the transaction, the executive vice president owned 6,156 shares in the company, valued at $4,011,249.60. The trade was a 46.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Nimrata Hunt sold 1,200 shares of the business’s stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $656.53, for a total value of $787,836.00. Following the transaction, the executive vice president owned 16,807 shares in the company, valued at approximately $11,034,299.71. This represents a 6.66% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 9,243 shares of company stock worth $6,018,650 in the last three months. 0.98% of the stock is currently owned by insiders.

IDEXX Laboratories Price Performance

Shares of NASDAQ:IDXX opened at $722.12 on Wednesday. The company has a market cap of $57.77 billion, a P/E ratio of 60.13, a P/E/G ratio of 4.06 and a beta of 1.62. The company has a quick ratio of 0.79, a current ratio of 1.11 and a debt-to-equity ratio of 0.31. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $735.00. The business has a fifty day simple moving average of $641.13 and a 200-day simple moving average of $574.15.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Monday, November 3rd. The company reported $3.40 EPS for the quarter, beating analysts’ consensus estimates of $3.14 by $0.26. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The business had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.07 billion. During the same quarter in the previous year, the business earned $2.80 earnings per share. The business’s revenue for the quarter was up 13.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. Equities research analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.